# Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

> **NCT05697809** · PHASE2 · COMPLETED · sponsor: **Oxular Limited** · enrollment: 3 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** OXU-001
- **DEVICE:** Semi-automated suprachoroidal illuminated microcatheter
- **DRUG:** Ozurdex® Ophthalmic Intravitreal Implant

## Key facts

- **NCT ID:** NCT05697809
- **Lead sponsor:** Oxular Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-07
- **Primary completion:** 2024-12-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05697809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05697809, "Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05697809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*